MedTrace Logo

International Registry on Cardioversion of Atrial Fibrillation (MK-6621-051)

NCT01119716 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 4658

Last updated 2024-06-12

Study results available
· View outcomes & findings →

Summary

This study will create a prospective registry of consecutive patients with Atrial Fibrillation (Afib) considered for cardioversion treatment to document up-to-date practice of in-hospital treatment, with a focus on the characterization of type of Afib, as well as on treatments applied (drugs, devices, interventions and their combinations), and associated complications within 60 days after enrollment.

Conditions

Sponsors & Collaborators

  • Institut für Herzinfarktforschung an der Universität Heidelberg

    collaborator UNKNOWN

  • Merck Sharp & Dohme LLC

    lead INDUSTRY

Principal Investigators

  • Medical Monitor · Merck Sharp & Dohme LLC

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-05-25
Primary Completion
2013-02-15
Completion
2013-02-15

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01119716 on ClinicalTrials.gov